Learning pointsFunctional mitral regurgitation and left bundle branch block are frequently present in patients with symptomatic severe left ventricular systolic dysfunction despite guideline-based optimal medical therapy, and pathways of care should be responsive to changing clinical circumstances.Cardiac resynchronization therapy (CRT) in accordance with current heart failure/CRT guidelines remains technically achievable in the presence of a Carillon^®^ Mitral Contour System^®^ annuloplasty device and can be accomplished as a day-case under local anaesthetic using standard techniques and equipment.

Introduction
============

Functional mitral regurgitation (FMR) is a common finding in cardiomyopathy patients with both ischaemic and non-ischaemic left ventricular systolic dysfunction (LVSD),[@ytz224-B1] being associated with worse symptoms and higher morbidity and mortality. The mitral valve is usually structurally normal, but ventricular (or atrial) dilatation or associated regional wall motion abnormalities can result in lateral displacement and mitral leaflet mal-coaptation leading to secondary (functional) mitral regurgitation (MR). The development of left bundle branch block (LBBB) can cause additional detriment, with cardiac resynchronization therapy (CRT) being a well-established recommended treatment, improving both symptoms and prognosis.[@ytz224-B2]

Timeline
========

  Date             Events
  ---------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  June 2013        Diagnosed with dilated cardiomyopathy. Symptoms stable on Bisoprolol 10 mg o.d., Ramipril 10 mg o.d., Spironolactone 25 mg o.d.
  May 2017         Presented acutely with chest pain and shortness of breath. Diagnosed as non-ST elevation myocardial infarction and heart failure exacerbation.Coronary angiogram: moderate diffuse coronary artery diseaseTransthoracic echocardiogram: mild-moderate eccentric mitral regurgitation (MR), severe left ventricular (LV) dilatation, and severe global left ventricular systolic dysfunction (LVSD)Managed medically
  November 2017    Seen in Heart Failure Clinic. Symptoms stable on optimized medical therapy (Bisoprolol 10 mg o.d., Sacubutril/Valsartan 200 mg b.i.d., Spironolactone 25 mg o.d., Ivabradine 5 mg b.i.d., Furosemide 80 mg o.d.). New York Heart Association (NYHA) Class II
  July 2018        Seen in Heart Failure Clinic. Worsening shortness of breath and orthopnoea, NYHA III/IV. Furosemide switched to Bumetanide 5 mg o.d.Transthoracic echocardiogram: moderate eccentric MR, severe LV dilatation, and severe global LVSD.12-lead electrocardiogram (ECG): sinus rhythm, heart rate 65 b.p.m., QRS 110 msTransoesophageal echocardiogram: severe eccentric MR
  August 2018      Community heart failure nurse review. Remains symptomatic with significant orthopnoea, paroxysmal nocturnal dyspnoea, and peripheral oedema. Increased diuretics caused worsening of gout symptoms. Remains NYHA III/IV
  September 2018   Carillon^®^ Mitral Contour System^®^ annuloplasty device implant as part of REDUCE-FMR trial
  October 2018     Seen in Heart Failure Clinic. Improvement in symptoms and NYHA II. Clinically euvolaemic
  January 2019     Seen in Heart Failure Clinic with worsening symptoms, peripheral and pulmonary oedema, and NYHA III/IV12-lead ECG: sinus rhythm, left bundle branch block (LBBB), and QRS 142 ms
  February 2019    Echocardiogram: mild MR, severe LV dilatation, and severe global LVSD
  March 2019       Remains symptomatic with reduced exercise tolerance, NYHA III12-lead ECG: sinus rhythm, PR interval 178 ms, LBBB, and QRS 148 ms
  April 2019       Cardiac resynchronization therapy with primary prevention defibrillator implanted
  June 2019        Symptomatic improvement, clinically euvolaemic, and NYHA II

Case presentation
=================

Chief complaint
---------------

A 60-year-old man with known heart failure with reduced ejection fraction (HFrEF) presented to Heart Failure Clinic in January 2019 with worsening symptoms of shortness of breath, new orthopnoea, and marked reduction in exercise tolerance \[symptoms graded as Class 3 of the New York Heart Association Functional Classification of Heart Failure (NYHA III)\], despite being on optimal guideline-based pharmacological therapy[@ytz224-B2] at the highest tolerated doses, consisting of Bisoprolol 5 mg b.i.d., Sacubitril/Valsartan 200 mg b.i.d., Spironolactone 25 mg o.d., and Bumetanide 5 mg o.d. Other regular medications consisted of Aspirin 75 mg o.d., Atorvastatin 40 mg o.d., and Metformin 1 g b.i.d. Additionally, a recent increase in loop diuretic dosage had exacerbated his gout symptoms. Physical examination revealed new pulmonary and peripheral oedema, with increased jugular venous pressure. Radial pulse was regular at 60 b.p.m., with a blood pressure of 100/70.

Past medical history
--------------------

Past medical history included dilated cardiomyopathy, non-ST-elevation myocardial infarction (diagnosed following presentation with troponin-positive chest pain and an angiogram revealing moderate diffuse coronary artery disease), Type 2 diabetes mellitus, obesity (body mass index 39), gout, and Carillon^®^ Mitral Contour System^®^ annuloplasty device implantation as part of the REDUCE-FMR trial[@ytz224-B3] in September 2018.

Investigations
--------------

Echocardiogram (February 2019, *[Figure 1B](#ytz224-F1){ref-type="fig"}*) showing severe LVSD and mild MR (previously moderate-severe on transthoracic and transoesophageal echocardiograms in July 2018, prior to Carillon^®^ device implant, [*Figure 1A*;](#ytz224-F1){ref-type="fig"}[Supplementary material online](#sup1){ref-type="supplementary-material"}, *Video S1*), known moderate diffuse coronary artery disease on coronary angiogram (2017), sinus rhythm with new LBBB on electrocardiogram (QRS duration 142 ms in January 2019, previously 110 ms in 2018).

![(*A* and *B*) Echocardiogram colour Doppler demonstrating the degree of mitral regurgitation prior to Carillon^®^ Mitral Contour System^®^ implant (*A*) and on repeat study in 2019 when symptoms deteriorated (*B*).](ytz224f1){#ytz224-F1}

Differential diagnosis
----------------------

His current deterioration in symptoms was deemed to be the result of developing LBBB with severe LVSD, despite initial symptomatic improvement following Carillon^®^ device implant and optimal medical therapy (OMT).

Management
----------

A decision was made to implant a CRT with primary prevention defibrillator (CRT-D) device, in accordance with the ESC guidelines on Cardiac Pacing and CRT.[@ytz224-B4]

Procedure
---------

The patient attended for CRT-D implantation in April 2019. The procedure was carried out under local anaesthetic and aseptic technique using a standard left infraclavicular incision and subclavian venous access. Using routine lead-placement procedures, a Medtronic 6947M internal cardioverter defibrillator dual-coil lead was positioned at the right ventricular apex and a Medtronic 5076 active lead was positioned in the right atrial wall with good variables.

The coronary sinus (CS) was cannulated using a standard pre-shaped CS guiding catheter (Attain system, Medtronic Inc., Minneapolis, MN, USA) with a standard MultiPurpose catheter. Retrograde contrast fluoroscopy revealed a large lateral vein (*[Figure 2A](#ytz224-F2){ref-type="fig"}*, [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Video S2*). A 4798-78 cm Medtronic left ventricular (LV) quadripolar lead was positioned in a stable mid-lateral position (*[Figure 2B](#ytz224-F2){ref-type="fig"}*).

![(*A* and *B*) Retrograde venography demonstrating potential tributaries of the coronary sinus and the Carillon^®^ Mitral Contour System^®^ (*A*) and the final position of the left ventricular lead (*B*).](ytz224f2){#ytz224-F2}

Follow-up
---------

The patient was discharged the same day uneventfully and was reviewed one week later in the pacing clinic for pacemaker parameter interrogation and incision area evaluation, with no issues identified. He has also reported a reduction in shortness of breath and resolution of orthopnoea symptoms on telephone consultation review with the HF specialist nursing team at 2 weeks; and was deemed to have a symptom burden of NYHA Class II when reviewed in the Heart Failure Clinic in June 2019 (see *Timeline*).

Discussion
==========

Guideline-based OMT can improve LV systolic function, reduce MR severity, and increase exercise capacity.[@ytz224-B1] In those with conduction delay, CRT is a well-established recommended treatment, improving FMR, symptoms, and prognosis.[@ytz224-B3]^,^[@ytz224-B5] For patients without a traditional CRT indication, surgical correction of FMR is not associated with improved outcomes.[@ytz224-B6] This has led to an increasing drive to find percutaneous techniques to reduce the FMR, with low peri-procedural risk.[@ytz224-B7] Recent trials have heightened anticipation that such percutaneous approaches might improve both symptoms and outcomes.[@ytz224-B2]^,^[@ytz224-B8]

Percutaneous mitral annuloplasty using the Carillon^®^ device is a fully transvenous approach utilizing the anatomical proximity of the CS to the mitral ring, that can lead to clinically relevant reductions in FMR.[@ytz224-B3] The device consists of distal and proximal anchors linked by a flexible nitinol bridge which, when deployed within the CS, can reduce FMR by externally restricting the mitral annulus diameter.[@ytz224-B3]^,^[@ytz224-B9]

However, HFrEF is a progressive disease process, one feature of which is the development of new conduction abnormalities.[@ytz224-B10] Observational studies have described an incidence of new-onset LBBB of up to 10% at 1 year even in ostensibly stable patients.[@ytz224-B11] New intraventricular conduction delay and QRS prolongation are associated with increased symptoms, worsening LV function, accelerated remodelling, increased risk of ventricular arrhythmias and sudden death and are an independent risk factor for all-cause mortality.[@ytz224-B12]^,^[@ytz224-B13] The presence of LBBB also predicts lower rates of reverse remodelling,[@ytz224-B14] and intraventricular conduction delay, especially LBBB is associated with worse FMR by lengthening LV isovolumetric contraction and relaxation. There is no evidence from observational studies or trials suggesting that device-based treatments for FMR are associated with the development of intraventricular delay or conduction abnormalities. Thus, our interpretation was that the development of new LBBB reported, in this case, is in keeping with the observed natural history of the underlying disease process.

There have been very few cases of CRT implantation in the presence of a Carillon^®^ Mitral Contour System^®^ annuloplasty device.[@ytz224-B15] The first reported case series by Hoppe *et al.* demonstrated the feasibility of successful CRT after percutaneous mitral annuloplasty, while in the other reported cases, the patients had pre-existing LBBB and ongoing symptoms following Carillon^®^ device implant.

Several concerns arise when contemplating LV lead implantation through the Carillon^®^ device, particularly around CS cannulation due to altered geometry and increased tortuosity or angulation. Other potential questions around lead positioning and stability and the risks of CS dissection have been raised.[@ytz224-B6] In practice, as can be seen from our image (*[Figure 1](#ytz224-F1){ref-type="fig"}*), the Carillon^®^ device provides easy visualization of the CS anatomy and orientation, facilitating direct access. Furthermore, tension from the device also reduces any tortuosity or angulation at the ostia of tributaries, potentially increasing the ease of LV lead placement. The conceivable risk of dislodgement of the Carillon system can be disregarded since intravascular-ultrasound data have demonstrated complete endothelialization of the anchors of the Carillon device within 6 months of implant.[@ytz224-B10]

Placing a Carillon^®^ Mitral Contour System^®^ over an existing transvenous CRT lead is currently not recommended, although a series of animal experiments demonstrated the feasibility and stability of the Carillon^®^ Mitral Contour System^®^ implanted in the presence of LV leads, and also that these leads could be extracted without migration of the Carillon^®^ device and without acute or long-term vascular complications.[@ytz224-B19]

Conclusion
==========

This case highlights the complexity of caring for a patient with symptomatic HFrEF, and that pathways of care should be responsive to changing clinical circumstances. We have demonstrated that a transvenous quadripolar LV lead can be safely implanted in the presence of a Carillon^®^ Mitral Contour System^®^ using standard implanting techniques under local anaesthetic as a day-case procedure.
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[Supplementary material](#sup1){ref-type="supplementary-material"} is available at *European Heart Journal - Case Reports* online.

**Slide sets:** A fully edited slide set detailing this case and suitable for local presentation is available online as [Supplementary data](#sup1){ref-type="supplementary-material"}.
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